SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Guggenheim Keeps Merck Among Top Large-Cap Biopharma Picks

Guggenheim maintained its Buy rating and raised its price target to $171 from $170, citing Merck's pipeline and upcoming clinical catalysts. RBC Capital maintained Sector Perform and cut its price target to $140 from $145.

MRKMRNA
SquawkNews Desk

Related stories

Procter & Gamble Closes $4 Billion Notes Offering Procter & Gamble closed a $4 billion notes offering. M impact | EQUITY | Oct 30, 2026, 08:24 PM UTC VantageScore CEO Silvio Tavares Steps Down; Anthony Hutchinson Named Interim CEO M impact | EQUITY | Oct 30, 2026, 08:22 PM UTC Twilio Reports Third-Quarter 2026 Revenue of $1.56 Billion Twilio reported revenue of $1.56 billion, up 19.9% year over year. Net income was $161.16 million, compared with $37.25 million a year earlier, and diluted EPS rose to $1 from $0.2 M impact | EQUITY | Oct 30, 2026, 08:22 PM UTC Ingersoll Rand Reports Third-Quarter 2026 Revenue of $2.06B Ingersoll Rand reported revenue up 5.6% year over year. Net income was $669.9M and diluted EPS was $1.73, versus $244.1M and $0.61 a year earlier. M impact | EQUITY | Oct 30, 2026, 08:22 PM UTC Weyerhaeuser Reports Third-Quarter Revenue of $1.862 Billion Revenue rose 8.4% to $1.862 billion from $1.717 billion a year earlier, while net income fell to $61 million from $80 million and diluted EPS declined to $0.08 from $0.11. M impact | EQUITY | Oct 30, 2026, 08:22 PM UTC Labcorp Reports Third-Quarter Revenue of $3.81 Billion, EPS of $3.22 Labcorp reported third-quarter 2026 revenue of $3.81 billion, up 6.9% year over year, and net income of $262.8 million, up 0.7%. Diluted EPS rose 3.2% to $3.22; growth reflected or M impact | EQUITY | Oct 30, 2026, 08:21 PM UTC